The U.S. Food and Drug Administration has approved vimseltinib for adult patients with a rare condition called tenosynovial ...
Tea will be served at 10:15 a.m., immediately preceding the seminar.AudienceThis seminar is open to the research community.
Tea will be served at 10:15 a.m., immediately preceding the seminar.AudienceThis seminar is open to the research community.
Tea will be served at 1:45 p.m., immediately preceding the seminar.AudienceThis seminar is open to the research community.
A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...
We treat every type of cancer, including the most important one: yours. With cancer, where you get treated first matters. From diagnosis to treatment, our experts provide the care and support you need ...
Thursday, March 20, 2025 - 2:00 p.m. to 3:00 p.m.
Ready to start planning your care? Call us at 800-525-2225 to make an appointment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback